St. Jude Medical, a global healthcare technologies manufacturer based in Little Canada, Minnesota, announced that the company’s updated cardiac resynchronization therapy defibrillators and Assuras ICDs received CE Mark approval from the European Union.
The newly-updated cardiac devices include upgraded algorithms to minimize the risk of unnecessary shocks. At the same time, the devices are able to maintain high peak levels of delivered energy for patients in cardiac arrest.
The new Assura suit of products includes the Fortify Assura ICD, the Unify Assura CRT-D and the Quadra Assura CRT-D. All the cardiac rhythm management systems feature the company’s proprietary Shockguard technology. With Shockguard, healthcare providers can minimize the risk of unnecessary or inappropriate shocks. Since inappropriate shocks are unpleasant for a patient, patients using an over-sensitive unit may not use it when needed. St. Jude Medical also received approval for the newly-updated Assura products from the United States Food and Drug Administration.
Eric Fain is the president of St. Jude Medical’s cardiac rhythm management division. In prepared remarks, he stated, "For some patients, the fear of receiving a shock can either prevent them from receiving a potentially life-saving device, or cause anxiety that reduces their quality of life once they receive the device.” He continued, "These devices directly address this patient concern and provides physicians additional tools to manage individual patient needs."
- Additive Manufacturing 101: How the Future of Product Development and Manufacturing is Changing - Video
- Microfluidics—A Powerful Technology for Diagnostic and Medical Product Development - Video
- Going Beyond Colour Matching . - Video
- Metal Injection Molding(MIM) for Precision metal components manufacturing - Supplier Resource
- Usage Temperatures of Piezoceramic Materials - Supplier Resource
- Breaking the Rules – Design Ideation and Innovation - Supplier Resource